Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
Antiviral Therapy - United Kingdom
doi 10.3851/imp3166
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
International Medical Press